"...the company is garnering takeover interest from large pharmaceutical companies. HZNP has a market cap of almost $18 billion and a typical takeover premium could see the company selling for well above $20 billion.
The takeover news also comes after speculation earlier this month that the company may be the target of an activist after a 13-F filing. Barclays added 3.56 million shares in 3Q, up from 288K in the prior quarter, Dealreporter and Gordon Haskett highlighted earlier this month. It's possible that an activist investor may have been accumulating the shares through Barclays."
The JP Morgan Annual Healthcare Conference scheduled for January 9th-12th in San Francisco could be VERYYYYYYY interesting this year.